Member Info for hunkymonkey

What about lanstead? - same there too? All these fund managers leaving at exactly the same time? Don't let the truth get in the way of a good story.

How do I know? Based on the fact that they have failed a phase 3 trial. Based on the fact that in terms of efficacy, $20000 pa lupuzor show little difference to steroids. Raising money when an sp is plummeting is difficult to do, when ii smell blood, they do not let you off the hook. It's the opposing view, one that's looked with a sense of logic and experience. 80%+ down since the results major shareholders selling out tells you that the guys with money are selling, not offering more. Interesting how do you know that they are? Who are they? How do you know they will come to anything? Look at prtk and couldn't find partners based on successful ph3?

That was always going to be the exact issue with the nature of the trial. Not big enough trial. All treated with steroids, however the nature of the disease, it's not easy to monitor. Ailments can differ from month to month. Is that lupuzor, is that steroids, is that a good month for the patient. The results are not good enough, end of, it isn't getting approved. Imm will not get funding for extra trials. So much trout around right now, all that's happening is a p&d to let bigger players out.. If the prospects were so great why was the sp £1.90 now under 30p.

What you're missing is the placebo that patients were given was steroids. There was no significant difference between the two. So without a much larger trial which Imm will never be able to fund, lupuzor is going no where fast. Unfortunately, for lupus sufferers too, the astrazenica trial is also going to take an extra 2 years. The patients need an effective treatment, unfortunately not this.

Love it, Simon works for £100bln company and fdbk, less than £10mln. He proceeds buys 2.3% of the company on the open market, it's not small fry considering the length of time he's been involved. It's a significant show of confidence and belief, it's bizarre people are trying to minimise that, especially considering the amount of bod that are not invested.

Last day of Hannover conference and all the products displayed may very well up for sale now. So maybe, just maybe, the is some news due

There's been another this week. The previous one resulted in the last rns on director dealings come to fruition. You never know

Thing is, however nailed on it is, it's now been circulating for 6 months. Prior getting fed up and moving on, the market now needs confirmation. Last day of the presentation for Bosch today at Hannover, so maybe next week?

There are not many bods as impressive as ours, but it's the payment via shares that I like. The tech is fundamentally sound, the connections that these guys have within the industry to deliver is outstanding. Very excited about this, good luck all

Bother not burgers. Lol the irony of that message though

I rarely burger with LSE, gibberish and nonsense from a total tool like doghouse.

That's one hell of a rerate if it all comes to fruition!!! Star is positioned better than most for short term rerate. Very exciting times

Kels - imm only needs 50k patients to be a blockbuster from over a mln patients worldwide, with no effective cure currently. The peptide can also be altered to treat other orphan autoimmune diseases. The potential revenues would be considerably higher with imm, that said there is a higher risk with imm as the results are not known. Ultimately one is manipulated and the other isn't

The absssi trial was a resounding success, the FDA said what they wanted and against who, and that's what we've delivered. Renal impairment patients could bring $bln revenues!!! Incredible!!! Oh wait......... The trials for habp going to start in the next ,4-5 months, as Iclaprim is attracted to the lungs and has proved safe with good efficacy so far, seems like a good combination - this could generate $700mln in revenues. Throw the cherry on the cake CF, with an endorsement from the CF Foundation, again seems logical for the same reasons as habp. All told this has the potential (in time) to become a multi-billion dollar drug, in a space desperate for new version antibiotics. Take all of the above I would say, patience will be more than rewarded. This will make some investors very wealthy indeed, but serve as a critical tool in the fight against super bugs in hospital and help save many lives. Hold tight and accumulate is my strategy.

I think we can expect some kind of imm type rise (eventually!!), 40% in a day and then kick on. We know that the risk here is much lower than pretty much all other pharma currently (as we've seen the results). We also all know the mcap is not indicative of success, so patience is required. The best thing is to hold and accumulate, as for news - if boa can accumulate 7% without affecting the sp. I think we can assume it'll move once the iis have had their fill

DMA, algorithms and whatever else is going on. All has to rectify at some point, further down the road of course, from what I have read, I feel assured that iclaprim will be approved. The biggest risk in my mind, can the bod market it effectively, well the answer in my mind is yes. The progress cannot be ignored indefinitely, despite what the trading suggests. I believe that iclaprim will be used in hospitals next year, generating revenue, which cannot be ignored!! Switching off and not getting distracted by the next big thing is the the hardest, as I was told in Vegas, never split a winning hand. That is what we're holding, this will be a success story of aim in a few years that people talk about

No panic, however people invest for different reasons, some invest on the basis of news, some have bagged and derisked, some are looking for 10-20% profit. All those people help to make a market. It's more often than not a good rule of thumb to take some profit though, for those who have read about the company, they are the most relaxed

More than the price, I am just pleased to see it moving a little more freely.

I wouldn't necessarily say the brakes are off, this is mtfb after all. However, I would say the game is clear now. 2018 should be a monumental year for us, patience has been and will be, your only enemy.

http://ir.motifbio.com/phoenix.zhtml?c=254416&p=irol-newsArticle&ID=2323741